Cargando…

No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis

The endothelium-derived vasoconstrictor molecule endothelin-1 (ET-1) has been suggested to play a role in the pathogenesis of Raynaud’s phenomenon (RP) and systemic sclerosis (SSc). We studied the effect of bosentan on microvascular structure and function in patients with RP secondary to limited cut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hettema, Martha E., Zhang, Dan, Stienstra, Ymkje, Smit, Andries J., Bootsma, Hendrika, Kallenberg, Cees G. M.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686804/ https://www.ncbi.nlm.nih.gov/pubmed/19350343 http://dx.doi.org/10.1007/s10067-009-1157-4

Ejemplares similares

Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors
por: Hettema, Martha E, et al.
Publicado: (2008)

Skin Autofluorescence, as Marker of Accumulation of Advanced Glycation Endproducts and of Cumulative Metabolic Stress, Is Not Increased in Patients with Systemic Sclerosis
por: Hettema, M. E., et al.
Publicado: (2011)

Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis: A case report
por: Omarjee, Loukman, et al.
Publicado: (2017)

The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome
por: Meijer, Jiska M., et al.
Publicado: (2007)

What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?
por: Kallenberg, Cees GM, et al.
Publicado: (2011)

Bosentan monohydrate
por: Kaur, Manpreet, et al.
Publicado: (2012)

Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers
por: Castellví, Ivan, et al.
Publicado: (2020)

Bosentan Does Not Affect Renal Resistive Index in Scleroderma/Systemic Sclerosis Patients
por: Di Poi, Emma, et al.
Publicado: (2023)

Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin
por: Hetzer, Sonja, et al.
Publicado: (2014)

Digital ulcers secondary to Sneddon’s syndrome successfully treated with Bosentan: not only useful in Systemic Sclerosis
por: Barnini, Tommaso, et al.
Publicado: (2012)

Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study
por: Corallo, Claudio, et al.
Publicado: (2016)

Effectiveness of bosentan in the treatment of systemic sclerosis-related digital ulcers: Systematic review and meta-analysis
por: Hosseinbalam, Marziyeh, et al.
Publicado: (2023)

Studies on the Vitrified and Cryomilled Bosentan
por: Minecka, Aldona, et al.
Publicado: (2021)

Retinal microvasculature alteration in patients with systemic sclerosis and chloroquine treatment
por: Huang, Tao, et al.
Publicado: (2022)

Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis
por: Murdaca, Giuseppe, et al.
Publicado: (2016)

Severe Calcinosis in Limited Cutaneous Systemic Sclerosis
por: Takizawa, Naoho, et al.
Publicado: (2017)

The effect of Bosentan on healing of colonic anastomosis
por: Cetinkaya, Ziya, et al.
Publicado: (2006)

Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007)

Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan
por: De Haro, Joaquin, et al.
Publicado: (2012)

Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality
por: De Almeida Chaves, Sébastien, et al.
Publicado: (2021)

Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension
por: Iannone, F, et al.
Publicado: (2008)

Rapid free thiol rebound is a physiological response following cold‐induced vasoconstriction in healthy humans, primary Raynaud and systemic sclerosis
por: Abdulle, Amaal Eman, et al.
Publicado: (2019)

Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports
por: Ito, Tomoki, et al.
Publicado: (2014)

Poverty-Related Diseases Attack Simultaneously
por: Thierry Barogui, Yves, et al.
Publicado: (2016)

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
por: Matucci-Cerinic, Marco, et al.
Publicado: (2010)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
por: Chinello, Pierangelo, et al.
Publicado: (2011)

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
por: Onda, Naomi, et al.
Publicado: (2014)

OA13 Multiple complication in the lifetime of limited cutaneous systemic sclerosis
por: Alkoky, Hoda, et al.
Publicado: (2022)

Hemorrhagic Cardiac Tamponade as a Complication of Limited Cutaneous Systemic Sclerosis
por: Sami, Faria, et al.
Publicado: (2023)

Altered ocular microvasculature in patients with systemic sclerosis and very early disease of systemic sclerosis using optical coherence tomography angiography
por: Mihailovic, Nataša, et al.
Publicado: (2022)

Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease
por: de Groot, Lodewijk, et al.
Publicado: (2011)

Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1
por: Akamata, Kaname, et al.
Publicado: (2014)

Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
por: Moinzadeh, Pia, et al.
Publicado: (2015)

Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan
por: Hostenbach, Stéphanie, et al.
Publicado: (2019)

Choriocapillaris microvasculature dysfunction in systemic hypertension
por: Chua, Jacqueline, et al.
Publicado: (2021)

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
por: Valerio, Christopher J, et al.
Publicado: (2009)

Ageing and microvasculature
por: Scioli, Maria Giovanna, et al.
Publicado: (2014)

Nailfold digital capillaroscopic findings in patients with diffuse and limited cutaneous systemic sclerosis
por: Shenavandeh, Saeedeh, et al.
Publicado: (2017)

Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
por: Pawar, Ravindra, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_h8203c0hq4aaki3pqodr22885s